Methylation status of individual CpG sites within Alu elements in the human genome and Alu hypomethylation in gastric carcinomas. 2010

Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital and Institute, Peking University School of Oncology, Haidian District, Beijing, 100142, China.

BACKGROUND Alu methylation is correlated with the overall level of DNA methylation and recombination activity of the genome. However, the maintenance and methylation status of each CpG site within Alu elements (Alu) and its methylation status have not well characterized. This information is useful for understanding natural status of Alu in the genome and helpful for developing an optimal assay to quantify Alu hypomethylation. METHODS Bisulfite clone sequencing was carried out in 14 human gastric samples initially. A Cac8I COBRA-DHPLC assay was developed to detect methylated-Alu proportion in cell lines and 48 paired gastric carcinomas and 55 gastritis samples. DHPLC data were statistically interpreted using SPSS version 16.0. RESULTS From the results of 427 Alu bisulfite clone sequences, we found that only 27.2% of CpG sites within Alu elements were preserved (4.6 of 17 analyzed CpGs, A approximately Q) and that 86.6% of remaining-CpGs were methylated. Deamination was the main reason for low preservation of methylation targets. A high correlation coefficient of methylation was observed between Alu clones and CpG site J (0.963), A (0.950), H (0.946), D (0.945). Comethylation of the sites H and J were used as an indicator of the proportion of methylated-Alu in a Cac8I COBRA-DHPLC assay. Validation studies showed that hypermethylation or hypomethylation of Alu elements in human cell lines could be detected sensitively by the assay after treatment with 5-aza-dC and M.SssI, respectively. The proportion of methylated-Alu copies in gastric carcinomas (3.01%) was significantly lower than that in the corresponding normal samples (3.19%) and gastritis biopsies (3.23%). CONCLUSIONS Most Alu CpG sites are deaminated in the genome. 27% of Alu CpG sites represented in our amplification products. 87% of the remaining CpG sites are methylated. Alu hypomethylation in primary gastric carcinomas could be detected with the Cac8I COBRA-DHPLC assay quantitatively.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm

Related Publications

Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
January 2018, Epigenetics,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
January 2000, Genetica,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
September 2004, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
September 1995, DNA and cell biology,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
October 2016, Bioinformatics (Oxford, England),
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
June 2011, Epigenetics,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
January 2018, International journal of mycobacteriology,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
May 2015, Gene,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
January 2013, PloS one,
Shengyan Xiang, and Zhaojun Liu, and Baozhen Zhang, and Jing Zhou, and Bu-Dong Zhu, and Jiafu Ji, and Dajun Deng
January 2013, BMC medical genomics,
Copied contents to your clipboard!